BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Mpilla GB, Philip PA, El-Rayes B, Azmi AS. Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations. World J Gastroenterol 2020; 26(28): 4036-4054 [PMID: 32821069 DOI: 10.3748/wjg.v26.i28.4036]
URL: https://www.wjgnet.com/1007-9327/full/v26/i28/4036.htm
Number Citing Articles
1
X. Liu, B. Chen, J. Chen, Z. Su, S. Sun. The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United StatesJournal of Endocrinological Investigation 2022;  doi: 10.1007/s40618-022-01985-2
2
Faten Cherchir, Ines Naceur, Ahmed Anas Haouari, Tayssir Ben Achour, Hajer Ben Mansour, Khadija Bellil, Fatma Said, Mohamed Habib Houman. Unilateral pseudouveitis revealing a pancreatic neuroendocrine carcinoma: A case reportClinical Case Reports 2022; 10(3) doi: 10.1002/ccr3.5563
3
Zhen Yang, Dongsheng Zhang, Guangjun Shi. Reappraisal of a 2-cm Cutoff Size for the Management of Nonfunctional Pancreatic Neuroendocrine Tumors: A Population-Based StudyFrontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.928341
4
Zhen Yang, Jie Liang, Kaiming Leng, Guangjun Shi. Survival Benefit of Surgical Resection for Pancreatic Neuroendocrine Tumors With Oligometastatic Liver Metastasis: A Retrospective and Propensity Score-Matching AnalysisFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.903560
5
Bor-Shiuan Shyr, Bor-Uei Shyr, Shih-Chin Chen, Yi-Ming Shyr, Shin-E Wang. Impact of tumor grade on pancreatic neuroendocrine tumorsAsian Journal of Surgery 2022; 45(12): 2659 doi: 10.1016/j.asjsur.2022.01.094
6
Xinchao Ban, Shengwei Mo, Zhaohui Lu, Congwei Jia, Huilin Shao, Xiaoyan Chang, Xinxin Mao, Yue Zhang, Junyi Pang, Yuhan Zhang, Shuangni Yu, Jie Chen. Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applicationsEndocrine 2022; 77(3): 538 doi: 10.1007/s12020-022-03102-y
7
Li Quan, Yongkang Liu, Wenjing Cui, Xinru Wang, Weixiao Zhang, Zhongqiu Wang, Chuangen Guo, Chao Lu, Feixiang Hu, Xiao Chen. The associations between serum high-density lipoprotein cholesterol levels and malignant behavior in pancreatic neuroendocrine neoplasmsLipids in Health and Disease 2022; 21(1) doi: 10.1186/s12944-022-01669-z
8
Hai-Feng Hu, Yu-Heng Hu, Xiao-Wu Xu, Zeng Ye, Xin Lou, Wu-Hu Zhang, Xue-Min Chen, Yue Zhang, Xian-Jun Yu, He-Li Gao, Jun-Yan Xu, Shun-Rong Ji. Role of Somatostatin Receptor 2 in Nonfunctional Pancreatic Neuroendocrine TumorsPancreas 2022; 51(10): 1404 doi: 10.1097/MPA.0000000000002199
9
Bokyung Ahn, Joo Young Kim, Seung-Mo Hong. Combined Infiltrative Macroscopic Growth Pattern and Infiltrative Microscopic Tumor Border Status Is a Novel Surrogate Marker of Poor Prognosis in Patients With Pancreatic Neuroendocrine TumorArchives of Pathology & Laboratory Medicine 2023; 147(1): 100 doi: 10.5858/arpa.2021-0475-OA
10
Mengfei Fu, Li Yu, Liu Yang, Yang Chen, Xiao Chen, Qinyu Hu, Hui Sun. Gender differences in pancreatic neuroendocrine neoplasms: A retrospective study based on the population of Hubei Province, ChinaFrontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.885895
11
Nian Guo, Zhen Liang, Li Jiao Xiong. Clinicopathological characteristics, survival outcomes and prognostic factors in the cT1N0M0 pancreatic neuroendocrine tumors: A SEER-based studyMedicine 2022; 101(41): e31019 doi: 10.1097/MD.0000000000031019
12
Ramazan GÜNDOĞDU, Serkan ERKAN, Hakan YABANOĞLU, M. Eda ERTÖRER, Esra Zeynep COŞKUNOĞLU, Fatma ÖZARSLAN. Pankreas Nöroendokrin Tümörlerinin Cerrahi Tedavisinde 11 Yıllık Tek Merkez DeneyimiHarran Üniversitesi Tıp Fakültesi Dergisi 2022; 19(2): 309 doi: 10.35440/hutfd.1126786
13
Mengfei Fu, Li Yu, Liu Yang, Yang Chen, Xiao Chen, Qinyu Hu, Hui Sun. Predictive value of the preoperative prognostic nutritional index for postoperative progression in patients with pancreatic neuroendocrine neoplasmsFrontiers in Nutrition 2022; 9 doi: 10.3389/fnut.2022.945833
14
Wei Li, Chao Xu, Zhaoxiang Ye. Prediction of Pancreatic Neuroendocrine Tumor Grading Risk Based on Quantitative Radiomic Analysis of MRFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.758062
15
J. E. Machado-Alba, M. E. Machado-Duque, A. Gaviria-Mendoza, I. N. Arsof-Saab, C. A. Castellanos-Moreno, L. Botero, L. Triana. Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumorsJournal of Endocrinological Investigation 2022; 46(1): 27 doi: 10.1007/s40618-022-01875-7
16
Samuel Frey, Eric Mirallié, Maëlle Le Bras, Nicolas Regenet. What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative ReviewCancers 2021; 13(23): 5954 doi: 10.3390/cancers13235954
17
Silke D. Werle, Nensi Ikonomi, Ludwig Lausser, Annika M. T. U. Kestler, Felix M. Weidner, Julian D. Schwab, Julia Maier, Malte Buchholz, Thomas M. Gress, Angelika M. R. Kestler, Hans A. Kestler. A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspectivenpj Systems Biology and Applications 2023; 9(1) doi: 10.1038/s41540-023-00283-8
18
Angela Ragone, Alessia Salzillo, Annamaria Spina, Silvio Naviglio, Luigi Sapio. Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell LinesFrontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.837503
19
Zhen Yang, Guangjun Shi. Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER databaseEuropean Journal of Surgical Oncology 2022; 48(10): 2181 doi: 10.1016/j.ejso.2022.05.016
20
Fei Wang, Jihyun Ma, Nan Zhao, Chi Lin, Haixing Jiang. Racial Disparities in Clinical Features and Survival Outcomes among Patients with Pancreatic Neuroendocrine Tumor: A Contemporary SEER Database AnalysisOncologie 2022; 24(4): 865 doi: 10.32604/oncologie.2022.025447